Explore the Potential with AI-Driven Innovation
The focused library is created on demand with the latest virtual screening and parameter assessment technology, supported by the Receptor.AI drug discovery platform. This method is more effective than traditional methods and results in higher-quality compounds with better activity, selectivity, and safety.
We pick out particular compounds from an extensive virtual database of more than 60 billion molecules. The preparation and shipment of these compounds are facilitated by our associate Reaxense.
The library features a range of promising modulators, each detailed with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Plus, each compound is presented with its ideal docking poses, affinity scores, and activity scores, ensuring a thorough insight.
We employ our advanced, specialised process to create targeted libraries for enzymes.
Fig. 1. The sreening workflow of Receptor.AI
It includes comprehensive molecular simulations of the catalytic and allosteric binding pockets and the ensemble virtual screening accounting for their conformational mobility. In the case of designing modulators, the structural changes induced by reaction intermediates are taken into account to leverage activity and selectivity.
Several key aspects differentiate our library:
partner
Reaxense
upacc
O75343
UPID:
GCYB2_HUMAN
Alternative names:
-
Alternative UPACC:
O75343; Q9NZ64
Background:
Guanylate cyclase soluble subunit beta-2 plays a pivotal role in intracellular signaling pathways. This enzyme is crucial for the conversion of GTP to cyclic GMP, a secondary messenger involved in vasodilation, platelet aggregation, and neurotransmission. Its precise mechanism and structure offer a fascinating area for biochemical research.
Therapeutic significance:
Understanding the role of Guanylate cyclase soluble subunit beta-2 could open doors to potential therapeutic strategies. Its involvement in key physiological processes suggests that modulating its activity could offer new avenues for treating cardiovascular diseases and neurological disorders.